Search
11 result(s) for 'author#Paul Harmatz' within BMC
Page 1 of 1
Sort by: Relevance | Date
-
Citation: Pediatric Rheumatology 2018 16(Suppl 2):52
-
Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance
Mucopolysaccharidosis (MPS) IVA or Morquio A syndrome is an autosomal recessive lysosomal storage disorder (LSD) caused by deficiency of the N-acetylgalactosamine-6-sulfatase (GALNS) enzyme, which impairs lysosom...
Citation: Orphanet Journal of Rare Diseases 2019 14:137 -
Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance
Mucopolysaccharidosis (MPS) VI or Maroteaux-Lamy syndrome (253200) is an autosomal recessive lysosomal storage disorder caused by deficiency in N-acetylgalactosamine-4-sulfatase (arylsulfatase B). The heterogenei...
Citation: Orphanet Journal of Rare Diseases 2019 14:118 -
Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)
Mucopolysaccharidosis II (MPS II; Hunter syndrome) is a rare, life-limiting lysosomal storage disease caused by deficient iduronate-2-sulfatase activity. Enzyme replacement therapy (ERT) with intravenous (IV) ...
Citation: Orphanet Journal of Rare Diseases 2021 16:456 -
Assessing the impact of the five senses on quality of life in mucopolysaccharidoses
The mucopolysaccharidoses (MPSs) are lysosomal storage disorders associated with progressive multi-organ and skeletal abnormalities. Clinical manifestations can affect each of the five senses: hearing, vision,...
Citation: Orphanet Journal of Rare Diseases 2020 15:97 -
Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure
Mucopolysaccharidosis type I (MPS-I) is a lysosomal storage disorder characterized by progressive multi-organ disease. The standard of care for patients with the severe phenotype (Hurler syndrome, MPS I-H) is ...
Citation: Orphanet Journal of Rare Diseases 2013 8:155 -
Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): defining and measuring functional impacts in pediatric patients
Research about pediatric patients’ perspective on mucopolysaccharidosis type VI (MPS VI) and its impact on daily life is limited. We aimed to identify the disease concepts of interest that most impact function...
Citation: Orphanet Journal of Rare Diseases 2021 16:500 -
Fetal therapies and trials for lysosomal storage diseases: a survey of attitudes of parents and patients
Lysosomal storage diseases (LSDs) are inherited metabolic disorders that may lead to severe multi-organ disease. Current ERTs are limited by anti-drug antibodies, the blood–brain barrier, and early disease ons...
Citation: Orphanet Journal of Rare Diseases 2022 17:25 -
Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry
Mucopolysaccharidosis type II (MPS II; Hunter syndrome; OMIM 309900) is a rare lysosomal storage disease with progressive multisystem manifestations caused by deficient activity of the enzyme iduronate-2-sulfa...
Citation: Orphanet Journal of Rare Diseases 2017 12:82 -
Mucopolysaccharidosis VI
Mucopolysaccharidosis VI (MPS VI) is a lysosomal storage disease with progressive multisystem involvement, associated with a deficiency of arylsulfatase B leading to the accumulation of dermatan sulfate. Birth...
Citation: Orphanet Journal of Rare Diseases 2010 5:5 -
Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects
High dose oral thiamine may have a role in treating diabetes, heart failure, and hypermetabolic states. The purpose of this study was to determine the pharmacokinetic profile of oral thiamine hydrochloride at ...
Citation: BMC Clinical Pharmacology 2012 12:4